Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 857,500 shares, a decline of 18.3% from the October 15th total of 1,050,000 shares. Based on an average trading volume of 146,200 shares, the short-interest ratio is currently 5.9 days. Currently, 4.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On Carisma Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the period. Wexford Capital LP raised its position in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Carisma Therapeutics during the 2nd quarter worth about $40,000. Finally, Vanguard Group Inc. lifted its holdings in Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after buying an additional 11,200 shares during the period. 44.27% of the stock is owned by institutional investors.

Carisma Therapeutics Price Performance

Shares of CARM traded down $0.06 during trading hours on Friday, reaching $0.88. The stock had a trading volume of 237,958 shares, compared to its average volume of 341,220. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. Carisma Therapeutics has a 12 month low of $0.80 and a 12 month high of $3.16. The stock has a market capitalization of $36.87 million, a PE ratio of -0.57 and a beta of 1.49. The company’s 50-day moving average is $0.98 and its two-hundred day moving average is $1.13.

Carisma Therapeutics (NASDAQ:CARM) last posted its earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). The firm had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. Research analysts expect that Carisma Therapeutics will post -1.33 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.